Zandelisib
- Generic Name
- Zandelisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C31H38F2N8O
- CAS Number
- 1401436-95-0
- Unique Ingredient Identifier
- 8Z28M5SX0X
- Associated Conditions
- -
- Associated Therapies
- -
Zandelisib + Tazemetostat in R/R Follicular Lymphoma
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Jacob Soumerai, MD
- Registration Number
- NCT05604417
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- MEI Pharma, Inc.
- Registration Number
- NCT05209308
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Stony Brook University, Stony Brook, New York, United States
🇺🇸OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT04745832
- Locations
- 🇺🇸
Mercy Clinic Cancer & Hematology - Chub O'Reilly Cancer Center, Springfield, Missouri, United States
🇺🇸Community Cancer Trials of Utah, Ogden, Utah, United States
🇨🇦Centre intégré universitaire de santé et de services sociaux de l'Estrie, Sherbrooke, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath